Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totalling 4,030,000 shares, a growth of 8.3% from the July 15th total of 3,720,000 shares. Based on an average trading volume of 454,500 shares, the days-to-cover ratio is currently 8.9 days.
Analyst Upgrades and Downgrades
CUE has been the subject of a number of recent research reports. JMP Securities lowered their price target on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a report on Friday, July 26th. Piper Sandler lowered their price target on shares of Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating for the company in a report on Friday, July 26th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $5.80.
Get Our Latest Research Report on Cue Biopharma
Institutional Trading of Cue Biopharma
Cue Biopharma Stock Up 11.9 %
Shares of CUE traded up $0.08 during mid-day trading on Monday, reaching $0.76. 306,256 shares of the stock traded hands, compared to its average volume of 350,045. The firm has a market cap of $36.97 million, a price-to-earnings ratio of -0.72 and a beta of 1.96. The stock has a fifty day simple moving average of $0.98 and a 200 day simple moving average of $1.57. Cue Biopharma has a 12-month low of $0.58 and a 12-month high of $3.25. The company has a quick ratio of 2.47, a current ratio of 2.47 and a debt-to-equity ratio of 0.11.
Cue Biopharma (NASDAQ:CUE – Get Free Report) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The company had revenue of $2.66 million for the quarter, compared to analyst estimates of $1.12 million. Cue Biopharma had a negative net margin of 711.84% and a negative return on equity of 128.30%. During the same quarter last year, the firm posted ($0.29) earnings per share. Sell-side analysts expect that Cue Biopharma will post -0.93 EPS for the current fiscal year.
About Cue Biopharma
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.
Featured Articles
- Five stocks we like better than Cue Biopharma
- P/E Ratio Calculation: How to Assess Stocks
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is Put Option Volume?
- 2 Option Strategies to Maximize Profits in a Bear Market
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.